The efficacy and safety of intravesical chondroitin sulphate solution in recurrent urinary tract infections

M. S. Rahnama'i1,2, A. Javan Balegh Marand2,3, K. Röschmann-Doose4, L. Steffens4* and H. J. Arendsen5

Abstract

Background: Urinary tract infections are among the most common indications for antibiotic therapy. The emergence of resistant uropathogens indicates the need for treatment alternatives. Replenishment of the glycosaminoglycan layer of the bladder, achieved by intravesical instillation of e.g. chondroitin sulphate (CS), is described to be a cornerstone in the therapy of cystitis. To retrospectively evaluate the efficacy of a therapy with 0.2% CS in patients suffering recurrent urinary tract infections (rUTI) in comparison to a treatment with low-dose long-term antibiotics (LDLTAB) and a combination of both.

Methods: A total of 151 patients with recurrent UTI who underwent intravesical therapy at Diaconesse hospital in Leiden, The Netherlands were included. 50 patients had been treated with CS, 51 patients had received LDLTAB, and 50 patients had received a combination therapy (LDLTABCS). Data recorded for baseline, after 6, and 12 months of treatment were evaluated. Descriptive statistics were calculated. Exploratory comparisons between groups and within groups were performed by using one-tailed and paired t-tests. Patients filled in a standardized quality of life questionnaire (EQ-5D).

Results: We found a statistically significant reduction of number of infections from $7.10 \pm 0.50$ SEM to $0.45 \pm 0.07$ SEM after 12 months therapy with CS compared to 12 months therapy with LDLTAB (from $7.04 \pm 0.47$ SEM to $1.8 \pm 0.15$ SEM). The number of visits to the urologist significantly decreased in the CS group from $7.46 \pm 0.80$ SEM to $1.28 \pm 0.11$ SEM and from $4.10 \pm 0.29$ SEM to $1.35 \pm 0.11$ SEM in the LDLTABCS group. In addition, a significant increase in Quality of life (QoL) was seen in the CS-group (from $58.2 \pm 0.82$ SEM to $80.43 \pm 0.82$ SEM) and in the LDLTABCS group (from $62.4 \pm 0.97$ SEM to $76.73 \pm 1.06$ SEM). There was no improvement in QoL with LDLTAB (from $58.24 \pm 1.08$ SEM to $58.96 \pm 1.19$ SEM). Evaluation's evidence is limited due to its retrospective character.

Conclusions: Retrospective analysis of data from patients that underwent therapy for rUTIs confirms the safety and efficacy of CS and indicate a superiority to antibiotic treatment of rUTIs.

Keywords: Recurrent urinary tract infections, Cystitis, Uropathogens, Intravesical instillation, Chondroitin sulphate, Antibiotic stewardship, Quality of life

Introduction

Typical symptoms of chronic and recurrent cystitis are dysuria, imperative urinary urgency, increased urinary frequency, and suprapubic pain. Affected patients suffer to a considerable degree from a massive decrease in
quality of life (QoL), induced by the increased urinary frequency, leading to social impairment [1–3].

Approximately 20% to 30% of women suffer from recurrent urinary tract infections (rUTIs), defined as two or more culture-proven UTIs in 6 months or three or more UTIs in one year [4, 5]. Although the etiology of UTIs is mainly bacterial and uropathogenic E. coli (UPEC) is the most common pathogen, antibiotic therapy does not reach a significant rate of success in preventing recurrent episodes [6]. As rUTIs likely result from the dysbiosis of gut microbiome leading to a persistent reservoir of UPEC in the intestine thus antibiotic treatment cannot attenuate but potentially facilitates the underlying cause [7].

Another potential cause of recurrent episodes is bacterial internalization and development of intracellular bacterial communities [8]. It is believed that bacterial attachment but also internalization is favoured by a damaged urothelial mucous membrane [8–10].

Furthermore, repeated antibiotic treatment increases the risk for developing drug resistance [11]. As shown within a long-term surveillance study the activity in terms of clearing the infection for (among others) Fosfomycin was found to decrease significantly over the 7-year study period [12] although much lower frequencies of resistance were observed in most European countries as well [13]. Given the alarming emergence of resistant uropathogens and the global increase in resistant strains [14, 15], sustainable treatment alternatives will support antibiotic stewardship.

A key element in the pathogenesis of chronic forms of cystitis is the glycosaminoglycan (GAG) layer, which regulates the penetration of solutes from within the urine to the bladder wall. The physiological function of this layer is to protect the urothelium. Endogenously produced chondroitin sulphate (CS) has been shown to be the dominant sulphated GAG on the urothelial luminal surface [9]. Many forms of chronic cystitis indicate a deficit in key elements of the GAG layer [16–19], which is regarded as an important element in the development of various diseases. A defect of the GAG layer promotes a chronically recurring infection as the protection from uropathogenic bacteria is reduced [18–21]. The replenishment of the GAG layer is described to be a cornerstone in the therapy of cystitis and the effectiveness of CS for treatment in chronic cystitis has been demonstrated [22–24]. CS with a concentration of 0.2% is in favour for the intravesical GAG layer replenishment therapy [25].

Gepan® instill is a certified and marketed class III medical device. It contains 0.2% sodium chondroitin sulphate (CS) as its physically effective component, and is instilled intravesically into the bladder and restores or reinforces the protective function of the GAG layer [26, 27].

The objective of this retrospective study was to evaluate the efficacy and safety of a therapy with 0.2% CS in patients suffering rUTIs in comparison to low-dose long-term antibiotics (LDLTAB).

**Material and methods**

**Patients**

Data retrospectively derived from 151 patients that underwent therapy for the treatment of rUTIs at Diaconessen Hospital Leiden (The Netherlands) were analyzed. Patients were chronologically selected from the hospital’s database based on start of treatment and the selection process was stopped, as soon as 50 patients per group were identified that met all in- and none of the exclusion criteria. 50 patients had been treated with 0.2% CS (CS), 50 patients with a combination of CS and low-dose long-term antibiotics (LDLTABCS), and 51 patients had received low-dose long-term antibiotics (LDLTAB). According to EAU guidelines [28], inclusion criteria focused on patients that experienced at least 3 episodes of uncomplicated cystitis in the last 12 months prior to the start of treatment, or 2 episodes in the last 6 months prior to the start of treatment as well as a positive culture of uropathogens at \( \geq 10^3 \) CFU/ml. Data from patients younger than 18 years, pregnant patients, patients with a positive urine culture of uropathogens \( \leq 10^3 \) CFU/ml, patients with urogenital defects/abnormalities, or a post voiding residual volume of \( >50 \) ml were excluded from this retrospective data analysis. Medical histories of the patients were documented prior to the start of treatment with CS and/or LDLTAB. Data recorded for baseline, after 6 months, and 12 months of treatment were evaluated for efficacy and safety of treatment.

**Study design and treatment regime**

Within hospital’s routine patients were asked, whether they would agree to evaluation and publication of data obtained during their treatment for research purpose and gave informed consent electronically. This retrospective analysis has been approved by the Ethics Committee at Diaconessen Hospital Leiden, in accordance with the provisions of the Declaration of Helsinki. Data of patients were not included within this analysis, if the in- and exclusion criteria were not met.

Prior to the start of treatment, the medical history of the past 12 month was documented. Additionally, the parameters defined were documented prior to start of the treatment, after 6 months, and after 12 months of treatment.

Patients received either CS and/or LDLTAB. According to the instructions for use and the treatment regime established at Diaconessen Hospital Leiden, patients receiving CS or LDLTABCS were treated with 40 ml of
0.2% CS solution (Gepan® instill) per instillation. The treatment was applied by a trained nurse under the supervision of the attending urologist, or by the urologist (see Additional file 1 for further details on the protocol for instillation). Following the first instillation, patients underwent the following protocol: weekly instillations for a duration of 6 weeks, followed by instillations every 2 weeks for 2 months, which were followed by instillations every 3 weeks for approximately 2 months, with subsequent instillations every 6 weeks up to a total duration of 1 year. For treatment with LDLTAB alone or in combination with CS patients received one of the following antibiotics decided by the physician in charge based on the treatment regimens valid at the hospital in accordance with respective treatment guidelines and based on the patient's individual characteristics and anamnesis on the individual antibiotic treatment: Furadantine® (Nitrofurantoin, 50 mg, 1 × day, 6 months), Noroxin® (Norfloxacin, 400 mg, 2 × day, 3 months), Augmentin® (Amoxicillin/clavulanic acid, 625 mg, 1 × day, 3 months), Monotrim® (Trimethoprim, 100 mg, 1 × day, 6 months) or Ciproxin® (Ciprofloxacin, 500 mg 1 × day, 3 months). Prior to the start of treatment, after 6 months of treatment, and after 12 months of treatment, patients filled in a standardized quality of life questionnaire (EQ-5D) according to the hospital's treatment routine.

Study parameters
Patient number, date of birth, gender and body mass index were noted to demographically describe the patients. The following documented parameters have been collected and evaluated: date of visits/start of treatment, confirmed dates of infections, positive urine culture for uropathogens (≥ 10^3 CFU/ml), identification of uropathogens, antibiotic sensitivity, prescribed antibiotic treatment, cystoscopy, QoL (EQ-5D), visits to the specialist.

Data management and evaluation
Pseudonymized data were obtained from Diaconessen Hospital Leiden. Patient identities were substituted by an identification code that was recorded on any form submitted to the sponsor of this data evaluation.

Data entry, check for quality and plausibility (double-checked each) and evaluation took place from March to July 2015. The following descriptive statistics were calculated: N (number of non-missing observations), mean (arithmetic mean), standard deviation (SD), standard error of the mean (SEM). For categorical data (nominal and ordinal variables) absolute and relative frequencies were calculated. Exploratory comparisons between groups and within groups were performed by using one-tailed and paired or unpaired t-tests.

The determination of the sample size was not based on biometric considerations. However, the sample size was considered to be sufficient to meet the objectives of this retrospective study.

Results
Demographic characteristics
Median age, BMI, and distribution of gender were comparable among the groups. The proportion of female patients within all groups investigated was high, reflecting the disease's target population (Additional file 1: Table S1).

Assessment of confirmed infections
Infections were confirmed by positive urine culture. In the majority of patients, E. coli was the most prominent uropathogen, with a minimum prevalence of 86% prior to the start of treatment. Other detected uropathogens were E. faecalis, Citrobacter, P. mirabilis and Klebsiella which were only of minor importance and prevalence declined even further to single occurrences at later stages of treatment (Additional file 1: Table S2). All uropathogens detected at baseline were tested and with exception of one case in the LDLTABCS group were found to be susceptible to treatment with AB. At 6 months follow-up 4 cases of detected E. coli in the LDLTABCS group were evaluated not to be susceptible to AB treatment.

Patients who received CS experienced 7.10 infection episodes (SEM ± 0.50) on average within 12 months prior to the start of treatment. After 6 months, number of infections showed a significant decline to 0.55 infections (SEM ± 0.08), and an additional reduction to 0.45 infections (SEM ± 0.07) after 12 months of treatment. Patients with LDLTABCS were initially assessed to have experienced 5.38 UTIs (SEM ± 0.34) within 12 months before the start of the treatment. After 6 months this number declined to 1.24 infections (SEM ± 0.08), and after 12 months the number of infections showed a further reduction to 0.26 infections (SEM ± 0.06). Patients that received LDLTAB experienced on average 7.04 infections (SEM ± 0.47) within 12 months prior to the start of the treatment. After 6 months this number declined to 1.24 infections (SEM ± 0.08), and after 12 months the number of infections showed a further decrease to 1.8 infections (SEM ± 0.15) after 12 months. As shown in Fig. 1, all treatments resulted in a significant decrease in the number of infections when periods before treatment were compared to the number of infections that occurred during the treatment period of 12 months. Reduction in infection rate as induced by CS and LDLTABCS was found to be significant when compared to LDLTAB. Furthermore, the number of infections showed a significant reduction with CS after 12 months of treatment, when compared to LDLTABCS.
Assessment of quality of life

Patients’ QoL was assessed in a standardized quality of life questionnaire (QoL; EQ-5D) prior to treatment and after 6 and 12 months of treatment. On a scale ranging from 0 to 100 patients that received CS had a score of 58.2 (SEM ± 0.82) before the start of treatment. After 6 and 12 months this score significantly increased to 71.60 (SEM ± 0.98) and 80.43 (SEM ± 0.82), respectively. Patients’ QoL scores in the LDLTABCS group initially showed a score of 62.4 (SEM ± 0.97), increasing to 71.5 (SEM ± 1.13) after 6 months, and 76.73 (SEM ± 1.06) after 12 months of treatment. The initial QoL score of patients that received LDLTAB alone was 58.24 (SEM ± 1.08). After 6 and 12 months of treatment the QoL scores in this group were 58.63 (SEM ± 1.04), and 58.96 (SEM ± 1.19), respectively, indicating no significant improvement (see Fig. 2).

Quantification of uropathogens

Prior to the start of treatment, after 6 months and after 12 months of treatment uropathogens were quantified from urine culture (Fig. 3), using standard microbiological methods. The urine cultures of the patients with CS initially showed an uropathogen load of 4.60 × 10^3 CFU/ml (SEM ± 0.29), which was markedly reduced to 0.83 × 10^3 CFU/ml (SEM ± 0.09) after 6 months, and 0.47 × 10^3 CFU/ml (SEM ± 0.08) after 12 months of treatment. Patients with LDLTABCS initially displayed an uropathogen load of 3.00 × 10^3 CFU/ml (SEM ± 0.16), with a clear decrease in bacterial load after 6 months with 1.26 × 10^3 CFU/ml (SEM ± 0.09) and 12 months with 0.26 × 10^3 CFU/ml (SEM ± 0.07), respectively. Patients with LDLTAB showed an initial titer of 4.00 × 10^3 CFU/ml (SEM ± 0.17), which only slightly decreased to 3.31 × 10^3 CFU/ml (SEM ± 0.20) after 6 months. After 12 months of treatment with LDLTAB, urine cultures still contained a substantial uropathogen load of 2.06 × 10^3 CFU/ml (SEM ± 0.18).

Assessment of visits at the urologist

Recurrent UTIs-induced visits to the urologist completed by patients within 12 months prior to the start of the treatment and during treatment were recorded and evaluated. Before the start of therapy patients treated with CS completed 7.46 (SEM ± 0.80) visits to the urologist. After 6 months the mean number of visits was reduced to 1.17 (SEM ± 0.10) and did not change remarkably after 12 months of treatment (1.28; SEM ± 0.11). Patients
that received LDLTABCS completed on average 4.10 (SEM ± 0.29) visits within 12 months prior to the start of the treatment. After 6 months the frequency of visits showed a notable reduction to 1.78 (SEM ± 0.10) visits, with a further decrease to 1.35 (SEM ± 0.11) visits after 12 months of treatment. As the number of visits to the specialist 12 months prior to the start of treatment was not available for patients receiving LDLTAB, only data obtained for 6 and 12 months of treatment could be evaluated. After 6 months of treatment, this group of patients on average completed 3.00 (SEM ± 0.17) visits at the urologist. This frequency showed a moderate reduction to 2.04 (SEM ± 0.17) visits after 12 months of treatment (data not shown). Treatment with CS alone or in combination with LDLTAB induced a significant decrease in doctor’s visits, whereby CS treatment resulted in a more pronounced decrease, with a significant reduction at the end of treatment when compared to the LDLTABCS group (Additional file 1: Fig. S1).

Safety
As this study was designed as retrospective analysis and only data from patients undergoing the complete therapy were included, no terminations of treatment due to the occurrence of any adverse event were recorded. However, for three patients that received CS mild to moderate burning feeling when urinating was documented after catheterization. Although no causality to CS was evaluated according to physician’s assessment, induction of these adverse events via the procedure of catheterization is possible. No adverse events were reported from patients receiving antibiotics.

Discussion
The aim of this study was to evaluate the efficacy of a treatment for rUTIs with either CS, LDLTAB or the combination LDLTABCS. The majority of patients were female (94% to 96%), reflecting the known prevalence for this disease [15]. The prevalence of E.coli, as confirmed by positive urine culture, was found to range from 86 to 100%, which is in line with data from literature where E.coli is described to be the predominant uropathogen with prevalence’s of 75–90% [5, 10].

During the course of the therapy with CS, the number of confirmed infections in patients was significantly reduced. In comparison with the LDLTAB group this decline was more pronounced in the CS group. Moreover, patients did not benefit from a combination of CS and LDLTAB, as QoL and visits at the urologist were comparable to the group of patients that received CS alone. Interestingly, CS instillation alone induced a significantly higher decrease in infection rate after 6 months when compared to the combination. Given the fact that the procedure of instillation bears additional risks for the induction of catheter-associated UTIs [29], the massive decrease of infection rates observed within the groups of patients that received CS bladder instillations might be even more substantial.

Compared to treatment with LDLTAB, urine cultures from patients that received CS clearly showed a more reduced uropathogenic load throughout the treatment period. Corresponding to the decrease in a number of infections and the identified uropathogenic load, treatment with CS also more distinctly reduced the number of specialist visits, when compared to patients that received LDLTAB.

Several studies have demonstrated that therapies utilizing intravesical instillations with hyaluronic acid and/or CS to replenish the GAG layer are more effective in reducing rUTIs than therapies with long-term antibiotics [6, 30–34]. In line with the findings of the present retrospective analysis, a combination of these therapies with LDLTAB failed to further contribute to the efficacy of treatment [6]. Given the worldwide spread of resistant strains, down-regulation of the use of antibiotics should be a primary aim. In addition to the increasing risk of resistant infections, this may also pose an additional risk of promoting the expression of virulence factors [35]. In this study, in total five cases of antibiotic resistance were observed corresponding to a frequency of 3% which matched the typically expected frequency [13, 36]. There clearly is a need to reevaluate the effectiveness of prophylactic strategies in patients with highly rUTIs, especially during short-term treatments, or when individuals are non-compliant. Besides the efficacy parameters that clearly indicate a superiority of CS bladder instillations in comparison to antibiotics, patients treated with CS also experienced a more pronounced increase in QoL, whereby patients < 60 years reached significantly higher QoL scores than patients ≥ 60 years (Data not shown).

As with all retrospective analyses of clinical data an underestimation of the occurrence of adverse events and in turn, an overestimation of the efficacy has to be considered, as only data from a patient that did not terminate the therapy were included in the evaluation.

Because of the retrospective character of this study we have no information about additional alternative treatments e.g. Cranberry or D-Mannose.

However, this evaluation clearly demonstrates the benefits of GAG replenishment as a treatment for rUTIs. This is in line with recent recommendations of the EAU for the treatment of rUTIs in adult women, where non-antimicrobial prophylaxis (e.g. endovesical instillations) is given priority over the use of antibiotics [37]. A recent study showed lasting clinical benefits for up to 36 months after end of treatment [38]. However,
well-designed large-scale clinical studies are needed to confirm these results and to provide solid evidence for guideline recommendations.

Abbreviations
CS: Chondroitin sulphate; GAG: Glycosaminoglycan; LDLTAB: Low-dose long term antibiotics; LDLTABCS: Low-dose long term antibiotics + chondroitin sulphate; QoL: Quality of life; rUTI: Recurrent urinary tract infection; SD: Standard deviation; SEM: Standard error of the mean; UPEC: Uropathogenic E. coli.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12894-022-01149-7.

Additional file 1. Methods: Protocol of instillations and antibiotic treatment. Table S1: Baseline patient characteristics (n = 50/51 per group). Table S2: Prevalence of bacterial pathogens in confirmed UTIs. Figure S1: Number of rUTI-induced visits to the urologist 12 months before and after treatment. Shown are mean values for number of visits per group; CS (n = 50, black bars), LDLTABCS (n = 50, grey bars); ** p = 0.009, *** p < 0.0001.

Acknowledgements
Not applicable

Author contributions
EA, KRD: Protocol/project development, EA: Data collection and management, EA, KRD, LS, LS: AIBM: Data analysis, SR, LS, KRD: Manuscript writing/editing, EA, SR, LS, KRD, AIBM: Critical revision of the manuscript. All authors read and approved the final manuscript.

Funding
The study was sponsored by G. Pohl-Boskamp GmbH & Co. KG, Hohenlockstedt, Germany.

Availability of data and materials
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This retrospective data analysis has been approved by the Ethics Committee at Ahligne Zeikhen Leiden, in accordance with the provisions of the Declaration of Helsinki. Patients were asked, whether they would agree to evaluation and publication of data obtained during their treatment for research purpose and gave informed consent electronically.

Consent for publication
Not applicable.

Competing interests
M.S. Rahnama’i reports fees from Farco Pharma and G. Pohl-Boskamp. K. Roschmann-Doose is an employee of G. Pohl-Boskamp. L. Steffens is an employee of G. Pohl-Boskamp. A. Javan Balegh Marand reports no conflicts of interest. H.J. Arendsen reports fees from G. Pohl-Boskamp during the conduct of the study.

Author details
1St. Elizabeth- Tweesteden Hospital, Tilburg, The Netherlands. 2Society of Urological Research and Education (SURE), Heerlen, The Netherlands. 3Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands. 4G. Pohl-Boskamp GmbH & Co. KG, Hohenlockstedt, Germany. 5Andros Clinics, Bladdercenter, The Hague, The Netherlands.

References
1. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161:553–7.
2. Hazewinkel MH, Stalpers LJ, Dijkgraaf MG, Roovers J-PW. Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies. Int Urogynecol J. 2011;22:725–30.
3. Loch A, Stein U. Interstitielle Zystitis. Der Urologe, Ausgabe A. 2004;43:1135–46.
4. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269–84.
5. Salvatore S, et al. Urinary tract infections in women. Eur J Obstet Gynecol Reprod Biol. 2011;156:131–6.
6. Torella M, et al. Intravesical therapy in recurrent cystitis: a multi-center experience. J Infect Chemother. 2013;19:920–5.
7. Worby CJ, Olson BS, Dodson KW, Earl AW, Hultgren SJ. Establishing the role of the gut microbiota in susceptibility to recurrent urinary tract infections. Clin Invest. 2022. https://doi.org/10.1172/jci158497.
8. Hannan TJ, et al. Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616–48.
9. Janssen DA, et al. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol. 2013;189:336–42.
10. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon. 2003;49:71–82.
11. Thantert R, et al. Comparative genomics of antibiotic-resistant uropathogens implicates three routes for recurrence of urinary tract infections. MBio. 2019. https://doi.org/10.1128/mBio.01977-19.
12. Sorlozano A, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control. 2014;42:1033–8.
13. Ny S, et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25–34. https://doi.org/10.1016/j.jgar.2018.11.004.
14. Grabe, M. et al. Edition presented at the 28th EAU Annual Congress, Milano.
15. Ho HJ, et al. Interaction between antibiotic resistance, resistance genes, and treatment response for urinary tract infections in primary care. J Clin Microbiol. 2019;57:e00143-61119.
16. Parsons CL, Greenberger M, Gabal L, Bidaire M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol. 1998;159:1862–7.
17. Parsons CL, Stein PC, Bidaire M, Lebov D. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn. 1994;13:515–20.
18. Ciccone A, et al. Restoring the glycosaminoglycans layer in recurrent cystitis: experimental and clinical foundations. Int J Urol. 2014;21:763–8. https://doi.org/10.1111/j.1442-2042.2013.02740.x.
19. Damiano R, Ciccone A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol. 2011;3:223–32. https://doi.org/10.1177/1756287211418723.
20. Meets JF. Interstitial cystitis: urgency and frequency syndrome. Am Fam Phys. 2001;64:1199–206.
21. Parsons CL, Zupkas P, Parsons JK. Intravesical potassium sensitivity in patients with interstitial cystitis and urethral syndrome. Urology. 2001;57:428–32.
22. Sorensen R. Chondroitin sulphate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Urol Suppl. 2003;2:16–8.
23. Nickel J, et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009;103:56–60.
24. Tutolo M, et al. A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroitin sulphate 2% for painful bladder syndrome/interstitial cystitis. Int Braz J Urol. 2017;43:134–41.
25. Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans—a review. Neurourol Urodyn. 2013;32:9–18.
26. Gauruder-Burmester A, Popken G. Zwei-Jahres-follow-up nach Einsatz von Natrium-Chondroitinsulfat bei der Behandlung der „Überaktiven Blase“. Geburts hilfe Frauenheilkd. 2009;68:1077–81.
27. Nordling J, van Ophoven A. Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung. 2007;58:328–35.
28. Grabe, M. et al. Guidelines on urological infections. Eur Assoc Urol 79 (2010).
29. Warren JW. Catheter-associated urinary tract infections. Int J Antimicrob Agents. 2001;17:299–303.
30. Constantinides C, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int. 2004;93:1262–6.
31. Damiano R, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59:645–51.
32. De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/ chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012. https://doi.org/10.1007/s00192-012-1794-z.
33. Lipovac M, et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynecol Obstet. 2007;96:192–5.
34. Porru D, et al. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2012;23:1193–9.
35. Goneau LW, et al. Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity. MBio. 2015;6:e00356-e1315.
36. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000–2009). BMC Infect Dis. 2013;13:1–14.
37. Grabe, M et al. Guidelines on urological infections. Euro Assoc Urol. 2015;182:237–57.
38. De Vita D, et al. Long-term efficacy of intravesical instillation of hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: 36 months’ follow-up. Clin Exp Obstet Gynecol. 2018;45:224–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.